Values First Advisors Inc. Has $820,000 Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Values First Advisors Inc. reduced its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 16.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,840 shares of the company’s stock after selling 3,885 shares during the quarter. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $820,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Creative Planning bought a new stake in shares of Mirum Pharmaceuticals during the third quarter worth approximately $249,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Mirum Pharmaceuticals by 10.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company’s stock valued at $4,526,000 after acquiring an additional 11,284 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Mirum Pharmaceuticals by 65.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company’s stock worth $358,000 after purchasing an additional 3,639 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in shares of Mirum Pharmaceuticals by 5.7% during the third quarter. Rice Hall James & Associates LLC now owns 242,711 shares of the company’s stock worth $9,466,000 after purchasing an additional 12,981 shares during the period.

Analyst Ratings Changes

Several equities analysts have weighed in on MIRM shares. HC Wainwright reissued a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $57.10.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the completion of the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,415 shares of company stock valued at $2,015,670 in the last 90 days. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $50.16 on Wednesday. The firm has a market cap of $2.41 billion, a P/E ratio of -24.83 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $53.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm’s 50 day moving average price is $44.97 and its two-hundred day moving average price is $42.47.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s revenue was up 89.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.57) EPS. On average, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.